Batavia Bioservices BV and UvA Holding BV announced today that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP(TM) technology developed by scientists at CellaGenics BV, an UvA Holding BV company.
Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP(TM) technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more then 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: “We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP(TM) technology since we firmly believe that this technology will significantly reduce manufacturing costs. Chris Yallop (COO Batavia Bioservices) added: “STEP(TM) technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop. Piet Scholten (Director UvA Holding BV) concluded: “With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!”